Resqunit AB (publ) announced its entry into a conditional agreement for the acquisition of intellectual property rights and a capital injection from Bio Vitos Norge AS. The intellectual property rights (the ?IPR?) acquired primarily encompass business assets related to the distribution and sale of health products containing Omega 3 (the "New Business"). The board of directors of the Company has evaluated the New Business as a significant opportunity to enhance the Company's potential for achieving positive cash flow in the short term.

Concurrent with the potential Acquisition, the Company will receive funding aimed at commercializing the Company?s existing business (the ?Existing Business?) to maximize its value realization. The Existing Business will continue to be conducted in Resqunit?s wholly owned subsidiary Resqunit AS (the ?Subsidiary?) with the ambition to further develop the values of the Existing Business and the Subsidiary over time. Any potential transfer of the Existing Business or the Subsidiary will only occur under circumstances that align with Nasdaq's requirements for the sustained operation of the Existing Business while the New Business undergoes further development.

The board's intention is to ensure that the existing shareholders of Resqunit, i.e. the shareholders of the Company prior to the completion of the New Issue (the ?Existing Shareholders?), shall be granted a right but not an obligation to acquire the shares in the Subsidiary. This shall be secured by Resqunit setting up another subsidiary (?Resqunit Intressenter?), which through an agreement with Resqunit shall be granted a purchase option (the ?Option?) to acquire all shares in the Subsidiary at a purchase price equal to the book value (or other optimized value determined by Resqunit) of the Subsidiary at time of purchase.